Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: N-Acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethano lamine
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

83461-56-7

83461-56-7 structure

Name: Mifamurtide
Chemical Name: mifamurtide
CAS Number: 83461-56-7
Molecular Formula: C₅₉H₁₀₉N₆O₁₉P
Molecular Weight: 1237.499
Catalog: Signaling Pathways Membrane Transporter/Ion Channel TRP Channel
Create Date: 2018-07-02 18:40:36
Modify Date: 2024-01-04 13:41:42
Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].

Name	mifamurtide
Synonyms	Mifamurtide muramyl tripeptide phosphatidylethanolamine (2R,5S,8R,13S,22R)-2-{[(3R,4R,5S,6R)-3-Acetamido-2,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]oxy}-8-carbamoyl-19-hydroxy-5,13-dimethyl-19-oxido-3,6,11,14,25-pentaoxo-18,20,24-trioxa-4,7,12 ;,15-tetraaza-19λ-phosphatetracontan-22-yl hexadecanoate N-Acetylmuramyl-alanyl-isoglutaminyl-alanyl-sn-glycero-3-phosphoethano lamine

Description	Mifamurtide(CGP19835; MTP-PE) is a drug against osteosarcoma.Target: OthersMifamurtide is an immunomodulator with antitumor effects that appear to be mediated via activation of monocytes and macrophages. Mifamurtide is generally well tolerated; adverse events attributed to administration of the drug include chills, fever, headache, nausea, and myalgias. Based on the available data, mifamurtide can be considered for inclusion in treatment protocols for localized osteosarcoma [1]. Mifamurtide has orphan drug status for the treatment of osteosarcoma in the US and EU [2].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> TRP Channel Research Areas >> Cancer
References	[1]. Frampton, J.E., Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs, 2010. 12(3): p. 141-53. [2]. Mifamurtide: CGP 19835, CGP 19835A, L-MTP-PE, liposomal MTP-PE, MLV 19835A, MTP-PE, muramyltripeptide phosphatidylethanolamine. Drugs R D, 2008. 9(2): p. 131-5.